Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RYZ101 Dose Level 1
RYZ101 · 3 trials · 18 indications
Incidence of DLTs during the first 56 days of study treatment will be assessed.
PFS will be defined as the time from the date of randomization until the date of progression (as determined by BICR from tumor assessments using RECIST v1.1) or death due to any cause, whichever occurs earlier.
Incidence rate of DLTs during the first 6 weeks of RYZ101 treatment
Incidence rate of DLTs during the first 6 weeks of study treatment
Progression Free Survival, defined as the time between first dose of study treatment and progression or death, as assessed by the investigator per RECIST v1.1 criteria
RP2D as determined by incidence rate of DLTs
Safety and tolerability of RYZ101 in combination with SoC as measured by incidence and severity of AEs including SAEs, laboratory changes and other safety findings
| Arm | Type | Description |
|---|---|---|
| Phase 1b - RYZ101 | EXPERIMENTAL | Part 1 is an uncontrolled dose de-escalation study to confirm the safety and determine the RP3D of RYZ101 based on Bayesian optimal interval design. |
| Phase 3 - RYZ101 | ACTIVE_COMPARATOR | Actinium 225 radiolabeled somatostatin analog (SSA) for injection |
| Phase 3 - Standard of Care | ACTIVE_COMPARATOR | Investigator's choice of standard of care between everolimus, sunitinib, octreotide, or lanreotide. |
| Phase 3 - RYZ101, PK/ECG Substudy adhoc subcohort | ACTIVE_COMPARATOR | Actinium 225 radiolabeled somatostatin analog (SSA) for injection |
| Monotherapy Dose Escalation | EXPERIMENTAL | Escalating doses of RYZ101 administered intravenously (IV) |
| Endocrine Therapy Combination Dose Escalation and Expansion | EXPERIMENTAL | RYZ101 in combination with investigator's choice of standard of care endocrine therapy |
| RYZ101 + SoC | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RYZ101 | DRUG | RP3D as determined in Phase 1b |
| Everolimus | DRUG | Everolimus |
| Sunitinib | DRUG | Sunitinib |
| Octreotide | DRUG | High-dose octreotide |
| Lanreotide | DRUG | Lanreotide |
| Standard of Care Endocrine Therapy | DRUG | Investigator's choice of endocrine therapy, such as, anastrozole, elacestrant, exemestane, fulvestrant, imlunestrant, letrozole, tamoxifen, or vepdegestrant |
| RYZ101 Dose Level 1 | DRUG | Dose Level 1 |
| RYZ101 Dose Level 2 | DRUG | Dose Level 2 |
| RYZ101 Dose Level 3 | DRUG | Dose Level 3 |
| RYZ101 Dose Level -1 | DRUG | Dose Level -1 |
| Atezolizumab | DRUG | Atezolizumab |
| Carboplatin | DRUG | Carboplatin |
| Etoposide | DRUG | Etoposide |
Inclusion: * Histologically proven, Grade 1-2 well differentiated, inoperable, advanced GEP-NETs (Ki67 ≤20%) Eastern Cooperative Oncology Group (ECOG) status 0-2. Ki67% \<20% is not required for the ad hoc subcohort of the PK/ECG substudy. * Progressive, SSTR-PET positive (i.e., Krenning score 3 or...
RYZ101 is an investigational small-molecule oncology therapy developed by Bristol-Myers Squibb Company (ticker BMY). It is being studied in gastroenteropancreatic neuroendocrine tumors, metastatic breast cancer, and extensive-stage small cell lung cancer. RYZ101 has received an Orphan Drug designation from the FDA and is in Phase 3 clinical development.
RYZ101 is being studied in gastroenteropancreatic neuroendocrine tumors that are SSTR-positive, well differentiated, and have progressed following 177Lu-SSA therapy. The Phase 3 trial compares RYZ101 with standard of care in adults with inoperable disease. RYZ101 is investigational and has not been established as a treatment for GEP-NET.
RYZ101 is developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. Bristol-Myers Squibb is the sponsor of the clinical program evaluating RYZ101 across gastroenteropancreatic neuroendocrine tumors, metastatic breast cancer, and extensive-stage small cell lung cancer.
RYZ101 is in Phase 3 clinical development. The Phase 3 trial, NCT05477576, is an active-controlled study in SSTR-positive well-differentiated GEP-NET that has progressed after 177Lu-SSA therapy, with enrollment of 343 participants. RYZ101 is investigational and is not approved by the FDA.
RYZ101 is being evaluated in three registered trials. NCT05477576 is a Phase 3 active-controlled study in GEP-NET. NCT06590857 is a Phase 1/Phase 2 trial in ER-positive, HER2-negative metastatic breast cancer expressing SSTRs. NCT05595460 is a Phase 1 study of RYZ101 combined with standard of care in SSTR-positive extensive-stage small cell lung cancer.
RYZ101 Dose Level 1 refers to a dose level of RYZ101, the investigational therapy developed by Bristol-Myers Squibb (BMY). RYZ101 is the drug name, and Dose Level 1 designates a specific dose studied within its clinical program. Both terms refer to the same agent.